|
| Wednesday, January 12, 2022 |
|
|
Apollomics Inc. to Host Virtual Investor Events on Wednesday, January 26, 2022 and Thursday, January 27, 2022 |
| Apollomics Inc. an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, today announced that the management team will host two upcoming webcasts to accommodate participants from the U.S. and China. more info >> |
|
| Tuesday, January 4, 2022 |
|
|
冠科美博（Apollomics）首席执行官余国良博士当选为百华协会 (BayHelix Group) 董事会主席 |
冠科美博（Apollomics Inc.）一家致力于发现和开发单药及组合肿瘤疗法的创新生物制药公司，今日宣布，冠科美博联合创始人、董事长兼首席执行官余国良博士最近被任命为百华协会董事会主席，此项任命自2022 年 1 月起生效。
more info >> |
|
|
冠科美博（Apollomics）首席執行官余國良博士當選為百華協會 (BayHelix Group) 董事會主席 |
冠科美博（Apollomics Inc.）一家致力於發現和開發單藥及組合腫瘤療法的創新生物製藥公司，今日宣佈，冠科美博聯合創始人、董事長兼首席執行官余國良博士最近被任命為百華協會董事會主席，此項任命自2022 年 1 月起生效。
more info >> |
|
|
Apollomics Inc. Announces CEO Guo-Liang Yu, PhD Appointed as Chairman of the Board for the BayHelix Group |
| Apollomics Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, today announced that Guo-Liang Yu, PhD, Co-Founder, Chairman and Chief Executive Officer of Apollomics, was recently appointed to Chairman of the Board for the BayHelix Group, effective January 2022. more info >> |
|
| Monday, November 22, 2021 |
|
|
冠科美博（Apollomics）Uproleselan 注射液（APL-106）用于治疗复发或难治性急性髓系白血病的中国 III 期临床试验第一例受试者成功入组 |
| 冠科美博（Apollomics Inc.），一家致力于发现和开发肿瘤单药及组合疗法的创新生物制药公司，今天宣布，Uproleselan 注射液（APL-106）用于治疗成人复发或难治性急性髓系白血病的中国 III 期临床试验第一例受试者成功入组。冠科美博已从 GlycoMimetics 获得 Uproleselan 在大中华区的授权许可。 more info >> |
|
|
冠科美博（Apollomics）Uproleselan 注射液（APL-106）用於治療復發或難治性急性髓系白血病的中國 III 期臨床試驗第一例受試者成功入組 |
| 冠科美博（Apollomics Inc.），一家致力於發現和開發腫瘤單藥及組合療法的創新生物製藥公司，今天宣佈，Uproleselan 注射液（APL-106）用於治療成人復發或難治性急性髓系白血病的中國 III 期臨床試驗第一例受試者成功入組。 more info >> |
|
|
Apollomics Inc. Doses First Patient in Phase 3 Clinical Trial with APL-106 (Uproleselan Injection) in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia |
| Apollomics Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, today announced that the first patient has been successfully dosed in a Phase 3 clinical trial of APL-106 (uproleselan injection) for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML) in China. more info >> |
|
| Friday, October 1, 2021 |
|
|
Edison Oncology和冠科美博（Apollomics）宣布EO1001(APL-122) I/IIa 期臨床試驗中首例患者接受治療 |
| Edison Oncology Holding Corp. (Edison Oncology)，一家致力於開發針對癌症的新療法的公司，和冠科美博（Apollomics Inc.），一家致力於發現和開發腫瘤靶向和免疫新藥及其組合療法的創新生物製藥公司，今天宣布，EO1001 (APL-122)已經完成首例患者研究給藥，這是一項在晚期實體瘤患者中進行的 I/IIa 期臨床試驗， EO1001是一款高效不可逆酪氨酸激酶抑製劑 (TKI)，在實驗室研究中已經證實作為單藥對EGFR(ErbB1)、HER2 (ErbB2) 和 HER4 (ErbB4) 有不可逆的抑製作用。 more info >> |
|
|
Edison Oncology and Apollomics Announce Treatment of First Patient by EO1001 (APL-122) in a Phase I/IIa Clinical Trial |
| Edison Oncology Holding Corp. ('Edison Oncology'), a company established to develop new therapies targeting the fight against cancer, and Apollomics Inc. ('Apollomics'), an innovative biopharmaceutical company committed to the discovery and development of mono- and combination oncology therapies, reported that the first patient was dosed with EO1001 (APL-122) in a Phase I/IIa clinical trial in patients with advanced solid tumors. more info >> |
|
|
Edison Oncology和冠科美博（Apollomics）宣布EO1001(APL-122) I/IIa 期临床试验中首例患者接受治疗 |
| Edison Oncology Holding Corp. (Edison Oncology)，一家致力于开发针对癌症的新疗法的公司，和冠科美博（Apollomics Inc.），一家致力于发现和开发肿瘤靶向和免疫新药及其组合疗法的创新生物制药公司，今天宣布，EO1001 (APL-122)已经完成首例患者研究给药，这是一项在晚期实体瘤患者中进行的 I/IIa 期临床试验， EO1001是一款高效不可逆酪氨酸激酶抑制剂 (TKI)，在实验室研究中已经证实作为单药对EGFR(ErbB1)、HER2 (ErbB2) 和 HER4 (ErbB4) 有不可逆的抑制作用。 more info >> |
|
|
|
|
